EGFR and neoplasm: The BR.21 study reported that both groups (tumours having EGFR mutations or wild-type EGFR) derive a survival benefit from treatment with erlotinib compared with placebo, although the effect of erlotinib was much greater in patients with EGFR-mutated tumours (Shepherd et al, 2005).